New Frontiers: The Role of CAR T-Cell Therapy in Multiple Myeloma.
Journal of the advanced practitioner in oncology(2022)
摘要
Multiple myeloma remains the second most common hematologic malignancy, and relapse rates are high, with refractory disease common with each relapse. Chimeric antigen receptor (CAR)-modified T cells are a promising new treatment, and at JADPRO Live Virtual 2021, presenters compared pivotal trials in CAR T-cell therapy for multiple myeloma, discussed how to recognize and manage common toxicities after CAR T-cell infusion, and reviewed pre-CAR-T consultation and post-CAR-T management.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要